Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.30 and traded as low as $0.27. Northwest Biotherapeutics shares last traded at $0.27, with a volume of 2,896,227 shares changing hands.
Northwest Biotherapeutics Price Performance
The firm has a market capitalization of $389.07 million, a price-to-earnings ratio of -3.62 and a beta of -0.51. The stock has a 50 day moving average price of $0.28 and a two-hundred day moving average price of $0.30.
Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.02) earnings per share for the quarter. The company had revenue of $0.36 million for the quarter.
Northwest Biotherapeutics Company Profile
(
Get Free Report)
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Featured Stories
Before you consider Northwest Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.
While Northwest Biotherapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
